Lamotrigine in children with refractory epilepsy

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Intractable epilepsy in children presents significant treatment challenges.
• Evaluating novel antiepileptic drugs is crucial for improving patient outcomes.

Purpose of the Study:

• To assess the efficacy and safety of lamotrigine (LTG) in pediatric patients with intractable epilepsy.
• To determine LTG's effectiveness across different seizure types.

Main Methods:

• Retrospective review of a prolonged video-electroencephalography (EEG) laboratory database.
• Inclusion criteria: pediatric patients with intractable epilepsy on LTG for ≥3 months.
• Analysis of seizure frequency reduction and adverse event incidence.

Main Results:

• Lamotrigine (LTG) achieved at least a 50% seizure frequency reduction in 57.1% of partial onset seizures and 53.6% of primary generalized seizures.
• Adverse events were infrequent (15%), with skin rash being the most common.
• LTG demonstrated efficacy in patients with various seizure types, including generalized and partial onset.

Conclusions:

• Lamotrigine (LTG) is an effective treatment option for pediatric intractable epilepsy, including both partial onset and primary generalized seizures.
• LTG exhibits a favorable side effect profile, supporting its consideration in refractory epilepsy cases.
• The study supports the use of LTG as an alternative to older antiepileptic drugs in pediatric populations.